Kineret (anakinra subcutaneous injection) — Cigna

Initial criteria

• The medication is being used for treatment of familial cold autoinflammatory syndrome (FCAS), Muckle-Wells Syndrome (MWS), and/or neonatal onset multisystem inflammatory disease (NOMID) formerly known as chronic infantile neurological cutaneous and articular syndrome (CINCA); AND
• The medication is prescribed by or in consultation with a rheumatologist, geneticist, allergist/immunologist, or a dermatologist

Reauthorization criteria

• Patient has been established on this medication for at least 6 months; AND
• Patient meets at least ONE of the following (a or b):
• a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating the requested drug); OR
• b) Compared with baseline (prior to initiating the requested drug), patient experienced an improvement in at least one symptom

Approval duration

initial 6 months; reauth 1 year